Pathophysiological aspects of insulin resistance in Atrial Fibrillation: novel therapeutic approaches
10.1186/s42444-021-00057-5
- Author:
Saira RAFAQAT
1
;
Sana RAFAQAT
;
Simon RAFAQAT
Author Information
1. Lahore College for Women University, Near Wapda Flats Jail Rd, Jubilee Town, Lahore 54000, Punjab, Pakistan
- Publication Type:REVIEW
- From:International Journal of Arrhythmia
2022;23(1):6-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Insulin resistance is associated with metabolic disorders including diabetes, obesity, hypertension, and inflammation which are the risk factors for Atrial Fibrillation. Many studies have reported that type 2 diabetes and AF are related and also their prevalence is increasing globally. Moreover, insulin resistance begins the type 2 diabetes.Main body: This review explains the pathophysiological aspects of insulin resistance in AF patients and discusses the drugs that are used to manage insulin resistance including Biguanides (metformin), thiazolidinediones (TZDs) [Pioglitazone, rosiglitazone], Sodium-glucose cotransporter 2 (SGLT2) inhibitors, Concentrated Insulin Products, Dipeptidyl peptidase-4 (DPP-4) Inhibitors, Glucagon-like peptide 1 (GLP-1) receptor Agonists, Pramlintide, Sulfonylureas, Meglitinides, α-Glucosidase Inhibitors, Colesevelam, Bromocriptine. This review will highlight a few major drugs that played a significant role in AF patients. For this purpose, many databases were used for reviewing the literature and keywords are used such as Insulin Resistance, Pathophysiology, Atrial Fibrillation, and Drugs.
Conclusion:This review article concludes that insulin resistance is related to AF. It also provides an outlook on the recent pathophysiological aspects of insulin resistance in AF; however, more studies are needed to clarify the management of insulin resistance in AF patients to prevent the development of type 2 diabetes.
